BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 10,580.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 610,152 shares of the biotechnology company’s stock after buying an additional 604,439 shares during the quarter. Pacer Advisors Inc. owned 0.32% of BioMarin Pharmaceutical worth $33,046,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Jump Financial LLC boosted its stake in shares of BioMarin Pharmaceutical by 530.3% during the 2nd quarter. Jump Financial LLC now owns 291,217 shares of the biotechnology company’s stock worth $16,008,000 after acquiring an additional 245,017 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares during the last quarter. AQR Capital Management LLC boosted its position in BioMarin Pharmaceutical by 90.7% during the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after purchasing an additional 2,654,768 shares in the last quarter. Covea Finance grew its holdings in BioMarin Pharmaceutical by 27.3% in the second quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock valued at $7,437,000 after purchasing an additional 29,000 shares during the last quarter. Finally, 1832 Asset Management L.P. acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at $1,431,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN opened at $59.95 on Friday. The company has a market cap of $11.52 billion, a P/E ratio of 22.54, a P/E/G ratio of 1.00 and a beta of 0.30. The business has a fifty day simple moving average of $54.39 and a 200-day simple moving average of $55.75. BioMarin Pharmaceutical Inc. has a 52 week low of $50.76 and a 52 week high of $73.51. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.20). BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The business had revenue of $776.13 million during the quarter, compared to analyst estimates of $782.42 million. During the same period in the previous year, the business posted $0.91 earnings per share. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analyst Ratings Changes

BMRN has been the topic of several recent research reports. Leerink Partnrs lowered shares of BioMarin Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. Morgan Stanley cut their target price on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. JPMorgan Chase & Co. increased their price target on shares of BioMarin Pharmaceutical from $116.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. Truist Financial raised their price objective on shares of BioMarin Pharmaceutical from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company reduced their target price on BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 28th. Sixteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $89.70.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.